website at www.sec.gov. Copies of the documents filed with the SEC by Stryker will be available free of
charge on Strykers website, www.stryker.com, or by contacting Strykers investor relations department at katherine.owen@stryker.com. Copies of the documents filed with the SEC by Wright will be available free of charge on Wrights
website, www.wright.com, or by contacting Wrights investor relations department at julie.dewey@wright.com. In addition, Wright shareholders may obtain free copies of the tender offer materials by contacting the information agent for the tender
offer that will be named in the Tender Offer Statement on Schedule TO.
Participants in the Solicitation
Wright, its directors and executive officers and other members of its management and employees, as well as Stryker and its directors and executive officers,
may be deemed to be participants in the solicitation of proxies from Wrights shareholders in connection with the EGM Proposals. Information about Wrights directors and executive officers and their ownership of Wright ordinary shares is
set forth in the proxy statement for Wrights 2019 annual general meeting of shareholders, which was filed with the SEC on May 17, 2019. Information about Strykers directors and executive officers is set forth in the proxy statement for
Strykers 2019 annual meeting of shareholders, which was filed with the SEC on March 20, 2019. Shareholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in
connection with the EGM Proposals, including the interests of Wrights directors and executive officers in the transaction, which may be different than those of Wrights shareholders generally, by reading the proxy statement and other
relevant documents regarding the transaction which will be filed with the SEC.
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ
materially from those implied by the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current
expectation of the Company and members of its senior management team and can typically be identified by words such as believe, expect, estimate, predict, target, potential,
likely, continue, ongoing, could, should, intend, may, might, plan, seek, anticipate, project and similar
expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, prospective performance, future plans, events, expectations, performance,
objectives and opportunities and the outlook for the Companys business; the commercial success of the Companys products, including the ability to achieve wide market acceptance of the Companys products due to clinical, regulatory,
cost reimbursement and other issues; filings and approvals relating to the proposed transaction; the expected timing of the completion of the proposed transaction; the ability to complete the proposed transaction considering the various closing
conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to
place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from
expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and other proposed transactions; uncertainties as to how many of the Companys shareholders will tender their shares in the
offer or approve the resolutions to be solicited at the extraordinary general meeting of the Companys shareholders; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived, including that a
governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the purchase agreement; the
effects of the proposed transaction (or the announcement thereof) on relationships with associates, customers, other business partners or governmental entities; transaction costs; the risk that the proposed transaction will divert managements
attention from the Companys ongoing business operations; changes in the Companys businesses during the period between now and the closing; risks associated with litigation; and other risks and uncertainties detailed from time to time in
documents filed with the SEC by the Company, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9, proxy statement and other documents to be filed by the Company. All
forward-looking statements are based on information currently available to the Company, and the Company assumes no obligation to update any forward-looking statements.